Stratrix
On the Record · Gilead Sciences

Gilead Sciences acquisitions, on the record

The businesses Gilead Sciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
CymaBay Therapeutics, Inc.
Word for word“In February 2024, we entered into a definitive agreement to acquire all of the outstanding common stock of CymaBay Therapeutics, Inc. (“CymaBay”) and its lead product candidate, seladelpar, which is an investigational treatment for primary biliary cholangitis, for approximately $ 4.3 billion.” 10-K for 2023
agreed acquisitionFebruary 2024approximately $ 4.3 billion
XinThera, Inc.
Word for word“In May 2023, we closed an agreement to acquire XinThera, Inc. (“XinThera”), a privately held biotechnology company focused on small molecule drugs to treat cancer and immunologic diseases, for approximately $ 200 million in cash consideration, net of cash acquired.” 10-K for 2023
acquisitionMay 2023approximately $ 200 million
Tmunity Therapeutics, Inc.
Word for word“In February 2023, we closed an agreement to acquire Tmunity Therapeutics, Inc. (“Tmunity”), a clinical-stage, private biotechnology company focused on next-generation CAR T-therapies and technologies.” 10-K for 2023
acquisitionFebruary 2023—
MiroBio Ltd
Word for word“On September 20, 2022, we acquired all of the outstanding share capital of MiroBio Ltd. (“MiroBio”), a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $ 414 million in cash.” 10-K for 2023
acquisitionSeptember 20, 2022$ 414 million
MYR
Word for word“In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company.” 10-K for 2023
acquisitionfirst quarter of 2021—
Immunomedics, Inc.
Word for word“For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics, Inc. in 2020, S&P Global Ratings downgraded our credit rating.” 10-K for 2023
acquisition2020—
Interius BioTherapeutics, Inc.
Word for word“In October 2025, we closed an agreement to acquire all outstanding shares of Interius BioTherapeutics, Inc. (“Interius”), a privately held biotechnology company developing in vivo chimeric antigen receptor (“CAR”) therapeutics, for approximately $ 350 million in cash consideration.” 10-K for 2025
acquisitionOctober 2025approximately $ 350 million in cash consideration
Arcellx, Inc.
Word for word“In February 2026, we entered into a definitive agreement to acquire Arcellx for an estimated $ 7.0 billion excluding our pre-existing common stock holdings, providing us with full control of its leading pipeline candidate, anitocabtagene autoleucel (“anito-cel”), an investigational BCMA-directed CAR-T cell therapy for patients with relapsed and/or refractory multiple myeloma.” 10-K for 2025
agreed acquisitionFebruary 2026an estimated $ 7.0 billion
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$0—
2017-12-31$10.43 billion—
2018-12-31$0—
2019-12-31$4.25 billion—
2020-12-31$25.92 billion$3.99 billion
2021-12-31$1.58 billion$226 million
2022-12-31$1.8 billion$0
2023-12-31$1.15 billion—
2024-12-31$4.84 billion—
2025-12-31$1.07 billion—

Deal filings since 2016

Read from Gilead Sciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.